Ascendis Pharma has been granted a patent for a long-acting growth hormone formulation designed to treat growth hormone deficiency in children. The method involves a bracketed dosing regimen, where dosage increases occur in a step-wise manner based on patient weight, ensuring tailored treatment for varying needs. GlobalData’s report on Ascendis Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ascendis Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Ascendis Pharma's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12016903B2 outlines a method for treating growth hormone deficiency in children through a long-acting growth hormone formulation. The method employs a bracketed dosing regimen, where patients are categorized into specific weight brackets, each receiving a standardized dose of the drug. The regimen allows for step-wise dosage increases across 3 to 20 weight brackets, ensuring that all patients within a bracket receive the same amount of growth hormone equivalents per week. Notably, the dosage is calibrated such that patients at the lower end of a weight bracket receive a dose that is 15-22% higher than those at the upper end. If a patient's weight exceeds the limit of a bracket, their dosage is adjusted to the next higher bracket, with a minimum increase of 10% in the growth hormone equivalents.
The patent further details various formulations and administration methods for the growth hormone, including lyophilized and liquid forms, which can be delivered via prefilled syringes, pen injectors, or dual chamber cartridges. The dosing regimen is designed to be sustained over a period of at least six months, with intervals of two to seven days between doses. The claims also specify that the increases in dosage between neighboring weight brackets can vary, with potential increments ranging from 15% to 40%. This structured approach aims to provide a tailored treatment for children with growth hormone deficiency, ensuring that the administration of the hormone is both effective and adaptable to individual patient needs.
To know more about GlobalData’s detailed insights on Ascendis Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
